Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×

Online ordering will be unavailable from 17:00 GMT on Friday, April 25 until 17:00 GMT on Sunday, April 27 due to maintenance. We apologise for the inconvenience.

  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Chapter 1.2 - Chapter

  • from 1 - Inflammatory Conditions
  • Edited by Derya Uluduz, Istanbul Üniversitesi
  • Anita Arsovska
  • Book:
    Rare Causes of Stroke
    Published online:
    06 October 2022
    Print publication:
    01 September 2022, pp 40-44

  • Summary

    Lymphomatoid granulomatosis is rare EBV mediated lymphoproliferative disorder occurring within the 4th to 6th decade, with most risk factors relating to an immunocompromised state. Histological analysis shows an angiocentric and angiodestructive infiltrate with varying degrees of necrosis and atypical EBV positive cells. The lungs are the primary site of involvement in over 90% of cases but central nervous system involvement can occur alongside or in isolation. Neurological presentation is varied and MRI commonly displays focal white matter parenchymal lesions. A brain biopsy may be required to exclude competing diagnoses or in the absence of identifiable disease elsewhere. Treatment depends on stage of disease and can range from observation, withdrawal of immunosuppressive regimes or aggressive chemo/immunotherapy

  • Survey of immunosuppressive acidic protein and other immunological parameters in head and neck cancer patients

  • Tadashi Nakashima, Motosuke Tanaka, Sei-ichi Okamura
  • Journal:
    The Journal of Laryngology & Otology / Volume 105 / Issue 11 / November 1991
    Published online by Cambridge University Press:
    29 June 2007, pp. 939-945
    Print publication:
    November 1991

  • Serum levels of immunosuppressive acidic protein (IAP) and other immunological parameters were examined in 95 head and neck cancer patients and 27 control patients. The mean values of IAP in patients in the advanced stage were significantly higher than in early stage patients. Statistically significant increases in the mean concentration of IAP were also observed in patients with a recurrence, as compared to findings in those in the advanced stages. The mean values of blastogenesis response to PHA and NK cell activity in the cancer patients were lower than in disease free individuals, but with no statistical differences. In the endstage patients, the lAP concentration was considerably elevated and the blastogenesis response showed a statistically significant decrease. Thus, the monitoring of serum lAP, in combination with other immunological parameters, aids in planning and assessing clinical staging in head and neck cancer patients.